MHRA: Xeal Pharma Clopidogrel Recall EL(26)A/43 Due to Underdosing

• Xeal Pharma has initiated a Class 2 Medicines Recall for all strengths of its Clopidogrel Oral Suspension and Oral Solution due to underdosing.
• A formulation error resulted in affected batches containing only 76% of the labelled clopidogrel amount.
• Pharmacists must contact patients dispensed these products, inform them of the lower dose, and advise against suddenly stopping the medication.
• Healthcare professionals need to review patient treatments, as no licensed oral clopidogrel suspensions are available.
• While no patient harm is anticipated, the recall emphasizes the critical need for robust quality control and compliance in pharmaceutical manufacturing.

Compliance officers and legal counsel must ensure that all steps, from stock quarantine and patient notification to communication with prescribers, are executed meticulously and without delay.

Xeal Pharma has initiated a Class 2 Medicines Recall, designated EL(26)A/43, for all strengths of its Clopidogrel Oral Suspension and Clopidogrel Oral Solution products. The company informed the Medicines and Healthcare products Regulatory Agency (MHRA) that these oral liquid formulations contain a lower concentration of the active ingredient, clopidogrel hydrogen sulfate, than stated on the label. This issue stems from a formulation error during manufacturing.

Specifically, the affected batches of Xeal Pharma Clopidogrel Oral Suspension and Oral Solution contain only 76% of the intended clopidogrel amount. All batches produced before the company's notification to the MHRA are impacted by this underdosing. The product in question is an unlicensed medicine, identified by the code MS 46688. While Xeal Pharma has confirmed that all future stock will be manufactured with the correct strength and calculations applied, the immediate concern is the existing supply of underdosed medication.

The MHRA has classified this as a Class 2 Medicines Recall, indicating a situation where the defect could cause harm, though not life-threatening. This classification necessitates a recall at the Patient, Pharmacy, and Wholesaler levels, demanding immediate action across the supply chain. Wholesalers and pharmacies are instructed to cease supplying the affected batches without delay, quarantine all remaining stock, and return it to their suppliers following established procedures.

Beyond stock management, the recall mandates proactive engagement with patients. Pharmacists are required to identify and contact all patients who have been dispensed these specific batches of Xeal Pharma Clopidogrel Oral Suspension. They must ascertain if patients still possess any of the recalled product. In instances where batch traceability information is unavailable, pharmacists are advised to contact all patients who received this product from July 20, 2026. Patients must be informed that the medication they received contained a lower dose than prescribed.

Despite the Clopidogrel underdosing formulation error, Xeal Pharma's risk assessment suggests that patient harm is not anticipated for individuals receiving the affected product for long-term preventative treatment. However, it is critical to acknowledge that patients have not been receiving their full, prescribed dose of clopidogrel. A crucial warning accompanies this Xeal Pharma Clopidogrel recall EL(26)A/43: patients and their carers must be reminded that abruptly discontinuing clopidogrel can lead to serious thrombotic events. Patients should not stop taking their medicine without medical advice.

Healthcare professionals, including prescribers, clinicians, and others involved in monitoring patients on Clopidogrel Oral Solution or Suspension, are urged to contact their patients or carers directly to review ongoing treatment. If a pharmacist identifies a patient with an impacted product, they should immediately contact the patient’s GP or prescriber to discuss the next steps. Given that there are no licensed clopidogrel oral suspension or solutions currently available, patients with affected batches may require a dose correction, a switch to alternative licensed formulations, or an entirely different treatment option. Patients are advised to continue taking their medicine as prescribed until a replacement is secured, then return the recalled product to their pharmacy. No reports of patient harm have been received concerning this issue, and the recall is being undertaken as a precautionary measure.

This Xeal Pharma Clopidogrel recall EL(26)A/43 highlights the critical importance of stringent quality control and robust recall protocols within the pharmaceutical industry. The Clopidogrel underdosing formulation error, leading to a MHRA Class 2 Medicines Recall, underscores the continuous need for UK pharmaceutical recall compliance. For pharmaceutical manufacturers, distributors, and pharmacies, this event serves as a stark reminder of the necessity for immediate adherence to Medicines and Healthcare products Regulatory Agency recall procedures.

Compliance officers and legal counsel must ensure that all steps, from stock quarantine and patient notification to communication with prescribers, are executed meticulously and without delay. The potential for regulatory non-compliance and future liability arising from underdosed products necessitates proactive and thorough quality assurance measures. This incident reinforces the principle that even in the absence of reported patient harm, the integrity of medication strength is paramount for patient safety and maintaining public trust in pharmaceutical products.

Compliance officers and legal counsel for pharmaceutical manufacturers, distributors, and pharmacies must ensure immediate adherence to MHRA recall procedures, including stock quarantine, patient notification, and communication with prescribers. This event underscores the critical importance of robust quality control and recall protocols to mitigate regulatory non-compliance risks and potential future liability from underdosed products.

Source: Original reporting via Medicines and Healthcare products Regulatory Agency